News

Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs

Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association. The funding from Target ALS and...

read more

Finding the right price: Key factors in negotiating license fees

Bio-Technopark, Auditorium, Wagistrasse 25, CH-8952 Schlieren Tuesday, October 22, 5 PM Setting the right price for licensing intellectual property is essential for fostering innovation and securing valuable partnerships. Whether you’re negotiating to out-license your own IP or in-license third-party rights, determining the right license fee structure is critical to your success. We will...

read more

Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems

September 18, 2024. ZURICH, Switzerland and NEWTON, Massachusetts, US. –GlobeNewswire– Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys’ Spectronaut® software with Thermo Fisher Scientific.  The agreement focuses on the co-marketing and co-selling of Biognosys’ Spectronaut software with...

read more

2nd Swiss Translational Medicine Conference

Join us for the 2nd Swiss Translational Medicine Conference, dedicated to translational medicine and entrepreneurship. We will showcase cutting-edge examples of how basic research, once completed, evolves into practical applications. This conference will highlight the various steps required along the translational journey, culminating in products or services that benefit society. This...

read more